Praxis Precision Medicines, Inc.

NASDAQ:PRAX

Biotechnology

Healthcare
$305.19 +4.49%

+$12.13 today

Market cap
$8.53B
Beta
2.75
P/E (TTM)
-25.0
EPS (TTM)
-$11.31
52W Low $37.19High $366.52

Volume 0.43M

Average 0.45M

PRAX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Praxis Precision Medicines, Inc.NASDAQ: PRAX

Gross Profit · Q3 FY2026 · quarter ended Sep 2026

Gross profit turns positive

Q3 FY2026 gross profit was $0, compared with -$65.8M a year earlier. Trailing-twelve-month gross profit was -$77.55M.

Context

  • Gross profit grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$19.39M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
-$140K+99.9% YoY
LTMSep 2026
-$77.55M+67.5% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year+99.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(140K) USD
Year-over-year change
+99.9%

Gross Profit vs competitors

How PRAX compares with its peers on the latest reported figures

  • PRAX's LTM Sep 2026 gross profit of -$77.55M is the lowest of the 10 companies compared; the peer median is $19M.
  • Its year-over-year change of +67.5% is the 3rd highest of 7, against a peer median of +48.5%.
PRAX Competitors Peer median
Gross Profit for PRAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$3.62B +37.2%+24.2%97.8%
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026$780.68M -18.9%+24.7%64.9%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$731.41M +24.2%+3.6%88.1%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$724.04M +59.9%+136.2%93.2%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$19M +2140.8%—95.0%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$0 ———
XENEXenon Pharmaceuticals Inc.LTM Sep 2026-$611K +99.1%-19.3%—
DNLIDenali Therapeutics Inc.LTM Jun 2026-$2.2M ——61.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026-$5.01M ———
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026-$77.55M +67.5%——
Peer median (excluding PRAX) $19M+48.5%+24.2%90.7%

Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue002.45M8.55M0
Cost of Revenue0154.44M86.77M152.41M140K
Gross Profit0(154.44M)(84.32M)(143.86M)(140K)
Gross Margin——-3445.8%-1682.0%—
Research & Development120.26M155.04M86.77M152.41M267.12M
Selling, General & Admin47.08M59.55M42.05M56.31M59.08M
Operating Expenses167.33M60.55M42.05M56.31M326.06M
Depreciation & Amortization182K419K432K358K140K
EBITDA(166.88M)(213.57M)(122.85M)(182.46M)(303.13M)
EBITDA Margin——-5020.2%-2133.3%—
Operating Income(167.33M)(214.99M)(126.37M)(200.17M)(326.2M)
Operating Margin——-5164.4%-2340.3%—
Interest Income00017.35M22.93M
Interest Expense00000
Other Income / Expenses271K957K3.1M17.35M22.93M
Income Before Tax(167.06M)(214.03M)(123.28M)(182.82M)(303.27M)
Pre-Tax Margin——-5037.9%-2137.5%—
Income Tax Expense00000
Net Income(167.06M)(214.03M)(123.28M)(182.82M)(303.27M)
Net Margin——-5037.9%-2137.5%—
EPS (Basic)(58.96)(69.33)(18.69)(10.21)(13.48)
EPS (Diluted)(58.96)(69.33)(18.69)(10.21)(13.48)
Weighted Avg Shares2.83M3.07M6.59M17.91M22.5M
Weighted Avg Shares (Diluted)2.83M3.07M6.59M17.91M22.5M

Praxis Precision Medicines, Inc.

NASDAQ:PRAX

Intrinsic Alpha fair value

Locked

Current Price

$305.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.